Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Pediatric Onset Multiple sclerosis: future challenge for early diagnosis and treatment
Presse Med. 2021 Jul 12:104069. doi: 10.1016/j.lpm.2021.104069. Online ahead of print.ABSTRACTMultiple sclerosis is a major socio-economical burden as it represents the most common cause of non-traumatic neurological disability in young adults [1]. It affects also children with a lower prevalence and incidence but remains a major concern as disability may occur later during their adulthood. Therefore, there is an absolute need for earlier diagnosis and treatment. In this review, we would focus on how these objectives can be achieved.PMID:34265375 | DOI:10.1016/j.lpm.2021.104069 (Source: Presse Medicale)
Source: Presse Medicale - July 15, 2021 Category: General Medicine Authors: Ali énor de Chalus M élanie Taveira Kumaran Deiva Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on treatment in multiple sclerosis
Presse Med. 2021 May 24;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the u...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Update on Treatment in Multiple Sclerosis
Presse Med. 2021 May 22:104068. doi: 10.1016/j.lpm.2021.104068. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the underst...
Source: Presse Medicale - May 25, 2021 Category: General Medicine Authors: Ilaria Callegari Tobias Derfuss Edoardo Galli Source Type: research

Rehabilitation in multiple sclerosis in 2020
Presse Med. 2021 May 11:104066. doi: 10.1016/j.lpm.2021.104066. Online ahead of print.ABSTRACTPatients with multiple sclerosis, despite advances in therapy, often suffer from locomotor impairment that limits their mobility and affect quality of life. Rehabilitation is part of the treatment of MS and has shown its beneficial effects in numerous studies. While traditional rehabilitation techniques remain in the limelight, new technologies are emerging and make it possible to improve the management of disabling symptoms. The aim of this update is to synthesize the new therapy techniques proposed in rehabilitation for patients...
Source: Presse Medicale - May 14, 2021 Category: General Medicine Authors: C écile Donzé Caroline Massot Source Type: research

Update on brain MRI for the diagnosis and follow-up of MS patients
Presse Med. 2021 May 11:104067. doi: 10.1016/j.lpm.2021.104067. Online ahead of print.ABSTRACTOver the past decades, MRI has become a major tool in the diagnosis and the follow-up of patients with multiple sclerosis (MS), especially for monitoring the effectiveness of therapy. The recent international recommendations issued for the standardization of neurological and radiological clinical practices converge on many points. In this setting, recommendations made by the "Observatoire Français de la Sclérose En Plaques", the French MS registry, can be distinguished by its interdisciplinary complementari...
Source: Presse Medicale - May 14, 2021 Category: General Medicine Authors: Jean-Christophe Brisset Sandra Vukusic Francois Cotton Source Type: research

Rehabilitation in multiple sclerosis in 2020
Presse Med. 2021 May 11:104066. doi: 10.1016/j.lpm.2021.104066. Online ahead of print.ABSTRACTPatients with multiple sclerosis, despite advances in therapy, often suffer from locomotor impairment that limits their mobility and affect quality of life. Rehabilitation is part of the treatment of MS and has shown its beneficial effects in numerous studies. While traditional rehabilitation techniques remain in the limelight, new technologies are emerging and make it possible to improve the management of disabling symptoms. The aim of this update is to synthesize the new therapy techniques proposed in rehabilitation for patients...
Source: Presse Medicale - May 14, 2021 Category: General Medicine Authors: C écile Donzé Caroline Massot Source Type: research